GLP1R and metabolic dysfunction-associated steatohepatitis: An open-label, phase 1/2 clinical trial in ten patients with biopsy-proven NASH improved liver enzymes as well as glycemic control via increase in serum levels of GLP-1, adiponectin, and T regulatory cells [74].